P

    Penumbra Inc (PEN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $323.06
    +1.38 (+0.43%)

    Market Cap: $12.67B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +238.46%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.18
    Range$1.07 - $1.29
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$1.27+7.3%
    60d ago$1.27+7.5%
    30d ago$1.28+8.3%
    7d ago$1.18+0.0%
    Current$1.18
    Revenue Consensus
    $400M
    Range$398M - $403M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.35
    Range$0.82 - $1.72
    11 analysts
    Revenue Consensus
    $431M
    Range$419M - $449M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.35---
    Sep 26EST
    		-$1.18---
    Jun 26
    Reported Jul 30
    		$0.88$1.15-23.48%Miss+2.3%
    Mar 26
    Reported May 6
    		$1.01$1.06-4.72%Miss+21.7%
    Dec 25
    Reported Feb 25
    		$1.18$1.10+7.27%Beat+21.6%
    Sep 25
    Reported Nov 5
    		$0.97$0.90+7.78%Beat+14.1%
    Jun 25
    Reported Jul 29
    		$0.86$0.82+4.88%Beat+34.4%
    Mar 25
    Reported Apr 23
    		$0.83$0.67+23.88%Beat+102.4%
    Dec 24
    Reported Feb 18
    		$0.97$0.89+8.54%Beat+27.6%
    Sep 24
    Reported Oct 30
    		$0.85$0.69+23.19%Beat+26.9%
    Jun 24
    Reported Jul 30
    		$0.64$0.56+14.29%Beat+48.8%
    Mar 24
    Reported May 7
    		$0.41$0.38+7.89%Beat+78.3%
    Dec 23
    Reported Feb 22
    		$0.76$0.70+8.57%Beat+375.0%
    Sep 23
    Reported Nov 2
    		$0.67$0.45+48.89%Beat+6600.0%
    Jun 23
    Reported Aug 1
    		$0.43$0.28+53.57%Beat+4200.0%
    Mar 23
    Reported May 2
    		$0.23$0.11+109.09%Beat+2400.0%
    Dec 22
    Reported Feb 23
    		$0.16$0.15+6.67%Beat+60.0%
    Sep 22
    Reported Nov 3
    		$0.01$0.01+0.00%Beat-91.7%
    Jun 22
    Reported Aug 4
    		$0.01N/A+133.33%Beat-95.2%
    Mar 22
    Reported May 3
    		$-0.01N/A-125.00%Miss-103.7%
    Dec 21
    Reported Feb 22
    		$0.10N/A-54.55%Miss-76.2%
    Sep 21
    Reported Nov 3
    		$0.12$0.17-29.41%Miss+100.0%
    Jun 21
    Reported Aug 9
    		$0.21$0.17+23.53%Beat+170.0%
    Mar 21
    Reported May 4
    		$0.27$0.09+200.00%Beat+575.0%
    Dec 20
    Reported Feb 23
    		$0.42$-0.07+700.00%Beat+90.9%
    Sep 20
    Reported Oct 28
    		$0.06$-0.08+175.00%Beat-76.0%
    Jun 20
    Reported Aug 3
    		$-0.30$-0.39+23.08%Beat-211.1%
    Mar 20
    Reported May 7
    		$0.04N/A-69.23%Miss-82.6%
    Dec 19
    Reported Feb 25
    		$0.22$0.19+15.79%Beat+69.2%
    Sep 19
    Reported Nov 7
    		$0.25$0.16+56.25%Beat+47.1%
    Jun 19
    Reported Aug 6
    		$0.27$0.22+22.73%Beat+80.0%
    Mar 19
    Reported May 7
    		$0.23$0.11+109.09%Beat+283.3%
    Dec 18
    Reported Feb 26
    		$0.13$0.12+8.33%Beat-80.9%
    Sep 18
    Reported Nov 5
    		$0.17$0.04+325.00%Beat+1600.0%
    Jun 18
    Reported Aug 7
    		$0.15$0.03+400.00%Beat+400.0%
    Mar 18
    Reported May 8
    		$0.06$-0.02+400.00%Beat+160.0%
    Dec 17
    Reported Feb 27
    		$0.68$-0.01+6900.00%Beat+950.0%
    Sep 17
    Reported Nov 7
    		$0.01N/A+120.00%Beat+125.0%
    Jun 17
    Reported Aug 8
    		$-0.05$-0.03-66.67%Miss-
    Mar 17
    Reported May 9
    		$-0.10$-0.05-100.00%Miss-
    Dec 16
    Reported Feb 28
    		$-0.08$-0.09+11.11%Beat-
    Sep 16
    Reported Nov 3
    		$-0.04N/A+63.64%Beat-

    Key Metrics

    Valuation
    P/E Ratio79.97EV/EBITDA54.88x
    Price/FCF58.89xFCF Yield1.70%
    Profitability
    Profit Margin10.70%Operating Margin10.50%
    ROE11.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.75xQuick Ratio3.86x
    Trading Statistics
    Beta0.70Avg Volume270.31K
    52-Week High$362.4152-Week Low$221.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$323.74
    SMA 20$324.71
    SMA 50$320.73
    SMA 200$323.67
    EMA 10$323.41
    EMA 20$323.44
    EMA 50$322.50
    EMA 200$315.54

    MACD

    Line: 0.38Signal: 1.01Hist: -0.63

    ADX

    ADX: 18.4+DI: 16.4-DI: 18.9

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down8.0
    PSAR$325.47

    Bollinger Bands

    Upper Band$328.29
    Lower Band$321.13
    %B Position220%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    49.9

    Momentum Oscillators

    Stoch %K13.2
    Stoch %D11.7
    Williams %R-71.3
    ROC (10d)-1.3%
    Momentum-4.11
    CCI (20d)-97.5
    MFI (14d)48.6

    Volatility Measures

    ATR (14d)$2.19(0.7%)
    StdDev (20d)1.79
    Hist Vol7.1%(Low)

    Volume Flow

    VWAP$322.61
    OBV12.8M
    AD Line-10.1M
    CMF (20d)0.009

    Volume Metrics

    Avg Vol (20d)267.4K
    Vol Ratio1.4x
    VWMA (20d)$324.39

    Pivot Points

    R3$323.76
    R2$323.01
    R1$322.34
    Pivot Point$321.59
    S1$320.92
    S2$320.17
    S3$319.50

    Advanced Oscillators

    TSI5.42
    Ultimate Osc47.0
    KST13.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$390.05M$374.76M$385.38M$354.69M$339.45M$324.14M$315.52M$301.04M$299.40M$278.65M$284.68M$270.95M
    Cost of Revenue$125.10M$121.35M$123.26M$114.27M$115.44M$108.26M$104.80M$100.73M$136.57M$97.52M$97.69M$93.23M
    Gross Profit$264.94M$253.41M$262.13M$240.42M$224.01M$215.88M$210.72M$200.31M$162.83M$181.14M$186.99M$177.72M
    Operating Expenses$223.91M$215.18M$202.90M$191.58M$183.18M$175.53M$167.95M$164.94M$243.79M$169.04M$151.96M$165.09M
    R&D$25.40M$22.38M$21.79M$22.68M$23.22M$22.08M$20.01M$25.20M$24.94M$24.63M$21.94M$39.17M
    SG&A$198.51M$192.79M$181.10M$168.90M$159.96M$153.46M$147.94M$139.74M$141.90M$144.41M$130.02M$125.92M
    Operating Income$41.04M$38.23M$59.23M$48.84M$40.83M$40.35M$42.77M$35.36M$-80,961,000$12.10M$35.03M$12.63M
    Interest Income$5.15M$3.45M$0$3.49M$4.48M$3.51M$0$4.41M$3.09M$2.52M$0$679,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$46.19M$41.69M$63.63M$52.33M$45.31M$43.86M$44.34M$39.78M$-77,874,000$14.63M$38.16M$13.30M
    Income Tax Expense$11.38M$9.10M$16.33M$6.47M$0$4.63M$10.66M$10.25M$-17,674,000$3.62M$-16,060,000$4.09M
    Net Income$34.81M$32.58M$47.34M$45.85M$45.27M$39.22M$33.68M$29.53M$-60,200,000$11.00M$54.22M$9.21M
    EBITDA$46.65M$42.81M$63.69M$51.33M$46.34M$45.37M$47.16M$39.51M$-73,314,000$19.62M$42.07M$19.56M
    EBIT$41.04M$38.23M$59.23M$48.84M$40.83M$40.35M$42.77M$35.36M$-80,961,000$12.10M$35.03M$12.63M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PEN

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Recent Awards

    Award IDAgencyObligatedStart
    36C24226P0817Department of Veterans AffairsDepartment of Veterans Affairs$0Jul 16, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    TFX or PEN: Which Is the Better Value Stock Right Now?

    This article analyzes Teleflex (TFX) and Penumbra (PEN) to determine which is a better value stock within the Medical - Instruments sector. Using Zacks Rank and Style Scores, it concludes that TFX is the better option due to its #2 (Buy) Zacks Rank, stronger earnings outlook improvement, and more attractive valuation metrics like a lower P/E ratio, PEG ratio, and P/B ratio compared to PEN.

    Yahoo Finance•8/26/26•
    Somewhat-Bearish

    Incuvate Files Patent Infringement Lawsuit Against Penumbra

    Incuvate, LLC has filed a patent infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit alleges that Penumbra’s THUNDERBOLT™ Neurovascular Thrombectomy System infringes five Incuvate patents related to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate is seeking damages, injunctive relief, and other remedies for the alleged unauthorized and willful infringement.

    The Manila Times•8/25/26•
    Neutral

    Incuvate Files Patent Infringement Lawsuit Against Penumbra

    Incuvate, LLC has filed a patent infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. Incuvate alleges that Penumbra's THUNDERBOLT™ Neurovascular Thrombectomy System infringes five of its patents related to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate is seeking damages, injunctive relief, and other remedies.

    FinancialContent•8/25/26•
    Bearish

    Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential And Market Position

    Penumbra, Inc. (PEN) is a prominent healthcare player with a $12.81 billion market cap, specializing in innovative medical devices like thrombectomy and embolization solutions. The company shows strong revenue growth of 14.90% and an 11.37% return on equity, backed by solid financials and a free cash flow of $161.1 million. While its valuation, including a high forward P/E, suggests a premium for future earnings, analyst ratings are cautiously optimistic, with an average target price indicating an 11.27% potential increase.

    DirectorsTalk Interviews•8/24/26•
    Bullish

    Penumbra Gets CE Mark for Thunderbolt Stroke Device in Europe

    Penumbra has received CE Mark approval for its Thunderbolt device, which is designed to treat ischemic stroke. This approval allows the device to be marketed in Europe. Thunderbolt is a part of Penumbra's advanced neurovascular access portfolio, offering physicians a new tool for clot removal in stroke patients.

    Moomoo•8/22/26•
    Neutral

    Frequently Asked Questions About PEN

    Does PEN pay dividends?
    Penumbra Inc (PEN) does not currently pay a regular dividend.
    What is PEN's P/E ratio?
    Penumbra Inc has a price-to-earnings (P/E) ratio of 79.97.
    What is PEN's market cap?
    Penumbra Inc (PEN) has a market capitalization of $12.67B with a current stock price of $323.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In